on TuHURA Biosciences, Inc.
TuHURA Biosciences Appoints Dr. Craig L. Tendler to Board
TuHURA Biosciences, Inc., a Phase 3 immuno-oncology company, has appointed Dr. Craig L. Tendler to its Board of Directors. Dr. Tendler brings extensive experience from his previous role as Vice President at Johnson & Johnson, where he oversaw 30 major drug approvals, including treatments for various cancers. His expertise in oncology drug development will be valuable as TuHURA progresses its IFx-2.0 immunotherapy candidate through clinical trials.
Dr. Tendler is recognized for achieving FDA Breakthrough Designations and global approvals for a range of oncology therapies. His background will support TuHURA’s strategy in overcoming resistance to cancer immunotherapy. With this new appointment, TuHURA aims to enhance its development programs and explore future collaborations and acquisitions.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all TuHURA Biosciences, Inc. news